New insights into the impact of checkpoint inhibitors on the immune system may enhance cancer treatment strategies. A ...

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for ...

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...